Literature DB >> 14706012

Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor.

Tomonori Yamanishi1, Kosaku Yasuda, Takao Kamai, Toshihiko Tsujii, Ryuji Sakakibara, Tomoyuki Uchiyama, Ken-ichiro Yoshida.   

Abstract

AIM: The aim of the present study was to compare the effectiveness of a cholinergic drug, an alpha-blocker and combinations of the two for the treatment of underactive detrusor.
METHODS: One hundred and nineteen patients with underactive bladder were assigned to three groups: the cholinergic group, consisting of 40 patients taking bethanechol chloride (60 mg/day) or distigmine bromide (15 mg/day); the alpha-blocker group, consisting of 38 patients taking urapidil (60 mg/day); and the combination group, consisting of 41 patients taking both a cholinergic drug and an alpha-blocker. The effectiveness of each therapy was assessed 4 weeks after initialization of the therapy.
RESULTS: Total urinary symptom scores (International Prostate Symptom Score, IPSS) remained unchanged after the cholinergic therapy, but were significantly lower after the alpha-blocker treatment (P = 0.0001) and the combination therapy (P = 0.0001). With regard to the total IPSS, there were significant differences between the cholinergic and the alpha-blocker groups (P = 0.0008), and also between the cholinergic and combination groups (P = 0.0033), in favor of the latter. The average and maximum flow rates did not increase significantly after monotherapy with either the cholinergic drug or the alpha-blocker, but they significantly increased after combination therapy compared to baseline values (P = 0.0033 and P= 0.0004, respectively). Postvoid residual volume did not decrease significantly after the cholinergic drug therapy, but decreased significantly after the alpha-blocker (P = 0.0043) and the combination therapies (P = 0.0008). The percentage of residual urine decreased significantly after therapy in all groups (P = 0.0005, P= 0.0176 and P= 0.0001, respectively).
CONCLUSION: Combination therapy with a cholinergic drug and an alpha-blocker appears to be more useful than monotherapy for the treatment of underactive detrusor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706012     DOI: 10.1111/j.1442-2042.2004.00753.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  30 in total

Review 1.  Underactive Bladder.

Authors:  Himanshu Aggarwal; Philippe E Zimmern
Journal:  Curr Urol Rep       Date:  2016-03       Impact factor: 3.092

Review 2.  Underactive bladder: A review of the current treatment concepts.

Authors:  Ömer Bayrak; Roger Roman Dmochowski
Journal:  Turk J Urol       Date:  2019-02-04

Review 3.  Voiding dysfunction due to detrusor underactivity: an overview.

Authors:  Marcus J Drake; Jonathan Williams; Dominika A Bijos
Journal:  Nat Rev Urol       Date:  2014-07-08       Impact factor: 14.432

Review 4.  Advanced therapeutic directions to treat the underactive bladder.

Authors:  Phillip P Smith; Pradeep Tyagi; George A Kuchel; Subrata Pore; Christopher Chermansky; Michael Chancellor; Naoki Yoshimura; Peter Levanovich
Journal:  Int Urol Nephrol       Date:  2014-09-20       Impact factor: 2.370

Review 5.  Updates of underactive bladder: a review of the recent literature.

Authors:  Xing Li; Limin Liao
Journal:  Int Urol Nephrol       Date:  2016-03-01       Impact factor: 2.370

6.  Transurethral incision of the bladder neck improves voiding efficiency in female patients with detrusor underactivity.

Authors:  Jia-Fong Jhang; Yuan-Hong Jiang; Hann-Chorng Kuo
Journal:  Int Urogynecol J       Date:  2013-11-28       Impact factor: 2.894

7.  [Diagnosis and therapy of functional disorders of the bladder in persons with diabetes mellitus. What do we actually know?].

Authors:  J Pannek
Journal:  Urologe A       Date:  2010-03       Impact factor: 0.639

Review 8.  Diagnosis and therapy for neurogenic bladder dysfunctions in multiple sclerosis patients.

Authors:  Giulio Del Popolo; Giovanni Panariello; Francesca Del Corso; Giuseppe De Scisciolo; Giuseppe Lombardi
Journal:  Neurol Sci       Date:  2008-12       Impact factor: 3.307

9.  Marked hydronephrosis and hydroureter after distigmine therapy in an adult male patient with paraplegia due to spinal cord injury: a case report.

Authors:  Subramanian Vaidyanathan; Paul Mansour; Bakul M Soni; Peter L Hughes; Gurpreet Singh; Tun Oo
Journal:  Cases J       Date:  2009-08-06

10.  Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: a 8-week prospective study.

Authors:  Kyu-Sung Lee; Deok Hyun Han; Young-Suk Lee; Myung-Soo Choo; Tag Keun Yoo; Heung Jae Park; Hana Yoon; Hyeon Jeong; Sun Ju Lee; Hayoung Kim; Won Hee Park
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.